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Abstract: The intestinal mucosal barrier prevents macromolecules and pathogens from entering
the circulatory stream. Tight junctions in this barrier are compromised in inflammatory
bowel diseases, environmental enteropathy, and enteric dysfunction. Dual sugar absorption
tests are a standard method for measuring gastrointestinal integrity, however, these are not
clinically amenable. Herein, we report on a dual fluorophore system and fluorescence detection
instrumentation for which gastrointestinal permeability is determined in a rat small bowel disease
model from the longitudinal measured transdermal fluorescence of each fluorophore. This
fluorophore technology enables a specimen-free, noninvasive, point-of-care gastrointestinal
permeability measurement which should be translatable to human clinical studies.
Published by The Optical Society under the terms of the Creative Commons Attribution 4.0 License. Further
distribution of this work must maintain attribution to the author(s) and the published article’s title, journal
citation, and DOI.

1.

Introduction

Intestinal permeability is increased in multiple intestinal disorders, including Crohn’s Disease,
celiac disease, graft vs. host disease, and environmental enteropathy and enteric dysfunction.
Permeability is also increased in extra-intestinal disorders such as types I and II diabetes, nonalcoholic fatty liver disease, and juvenile and adult inflammatory arthritidies [1–5]. Interestingly,
first degree relatives of people with Crohn’s Disease, who are at increased risk for the development
of this disorder, also have increased permeability [6–8].
The prevalence of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative
colitis, is estimated to be 1.2 million people in the US [9], and the total annual economic burden
of IBD in the US is estimated to exceed $10 billion [10]. Prevalence of celiac disease is estimated
to be 1:70 to 1:300 [11]. The value of earlier detection and anticipatory disease management in
such illnesses is substantial [12]. However, current disease monitoring strategies are expensive
(colonoscopies), invasive (blood tests), or cumbersome (stool tests).
Intestinal permeability in humans has most commonly been determined using the dual sugar
absorption test (DSAT), where patients drink a solution containing a disaccharide, usually lactulose
(MW = 342), and a monosaccharide, either mannitol (MW = 182) or rhamnose (MW = 164).
These molecules enter the circulation from the gut and are excreted intact into the urine. The
urinary ratios of lactulose to mannitol (or lactulose to rhamnose) are used to indicate the degree of
intestinal permeability, with increased permeability characterized by an elevated ratio reflecting
the heavier disaccharide entering into circulation [13–17]. These DSATs are theoretically sound,
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Animals

The Animal Studies Committee of the Washington University School of Medicine approved
the animal protocol. Indomethacin-induced small bowel injury in female Sprague-Dawley rats
(Charles River, Kingston, NY) was used as the model [21–27]. Indomethacin (Sigma, St. Louis,
MO) was suspended in 2% methylcellulose (Sigma, St Louis, MO) in water, at a concentration of
3.75 mg/mL.
2.3.

Experimental set-up and procedures

On the day prior to the oral tracer gavage, 4 mL/kg of the indomethacin solution vehicle was
administered via gavage (approximately 18-20 hours prior to oral tracer gavage) to induce gut
lesions in the designated rats. This corresponded to a challenge dose of 15 mg/kg. Vehicle alone
(2% methylcellulose) was used for the non-injury control rats, also administered at a volume
of 4 mL/kg. Following either of these gavages, a 2.5 × 2.5 cm area on the anterior section of
each animal’s back was shaved and treated with depilating cream, necessary for the transdermal
experiments described below.
On the following day (day of the oral tracer gavage), animals were anesthetized with 1.5%
Isofluorane, and a catheter inserted into their urinary bladder. The fluorophore tracer gavage
mixture was prepared consisting of 46 mg/mL MB-404 and 8 mg/mL MB-301, and administered
at 2 mL/kg yielding a dose of 92 mg/kg MB-404 and 16 mg/kg MB-301.
The anesthetized animals were placed prone (Fig. 2) and the depilated area was wiped with
a ChloraPrep One-Step (CareFusion, 260299) skin prep applicator, followed by wiping with a
Cavilon (3M 3344) applicator. A 2.5 × 2.5 cm medical adhesive (3M 1577) was placed over
the prepped area. A bifurcated fiber optic bundle for light excitation delivery and fluorescence
emission collection, outfitted with a Vascular Access Harness (Instech Labs CIH105), was gently
placed against shaved area. A holding arm for the fiber optic bundles (located to the right of each
bundle in Fig. 2) was used to support the weight of the cable.
Transdermal fluorescence detection was initiated and baseline fluorescence was acquired for
10 minutes. Animals were then removed from the anesthesia holder for vertical gavage with the
fiber optic bundle remaining attached. The animals were placed into the anesthesia manifold
following gavage. Animals were gavaged sequentially.
2.4.

Collection and analysis of fluorophores in urine

Urine was obtained before fluorophore gavage (T0 ), and then at 30, 60, 120, 180, 240, 300,
360, 420, and 480 minutes after fluorophore gavage. Urine volumes were recorded at each time
point and pooled together in a tube for the entire period of experiment for each animal in this
study. Samples were cooled in an ice bucket before freezing (−80 °C), and remained frozen until
analysis.
MB-301 and MB-404 concentrations in urine were determined using a Waters Alliance
2695 HPLC system, or a Waters Acquity H Class UPLC system, equipped with column heater,
sample heater/cooler, vacuum degasser, autosampler, binary gradient pump, and fluorescence
detector. A Phenomenex Luna C18 (2), 4.6 × 250 mm, 5 µm, 100Å RP-HPLC analytical column
(Phenomenex, Cat No. 00G-4252-E0, S/N H15-133556) with a Security Guard Cartridge C18
(4 × 3 mm ID, 5 µm) (Phenomenex, Cat. No. KJ0-4282) were employed for urine sample
fluorescence analysis under the HPLC gradient conditions described as follows: Two mobile
phases, A: 0.1% TFA/H2 O and B: 0.1% TFA/ACN were used. The run started with 3 minutes
equilibration at 95A/5B, then linear gradient to 60A/40B from 3–10 minutes to separate MB-301
and MB-404. The column was regenerated at 10A/90B from 10.05–12 minutes and at 95A/5B
from 12.05–15 minutes.
On the day of analysis, urine samples were thawed to room temperature, and vortexed at
high speed for 10 seconds. Ten µL of urine samples were diluted into 990 µL of 1X PBS in
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Fig 2. Experimental set-up for in vivo transdermal fluorescence acquisition and urine
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system, one of the four bifurcated fiber bundles, and one of the four detection channels. Fiber
bundles 2–4 and detection channels 2–4 have been omitted for the sake of simplifying the diagram
but were identical in their implementation to fiber bundle 1 and detection channel 1. The common
end of all four fiber bundles is visible in Fig. 2.

tissue

Fig. 3. Transdermal fluorescence detection system schematic illustrating the illumination
system and one of four identical detection channels. (Filter center wavelengths given with
full width at half maximum bandwidth (FWHM).)

The illumination sources were a 402 and a 505 nm light-emitting diode (LED) (Lightspeed
Technologies Inc., Model LEDH-402 and LEDH-505), each packaged in a driver with integrated
optics (Lightspeed Technologies Inc., Model HPLS-36AD3500). LED emission was collimated
(Lightspeed Technologies Inc., Model OH36-24 × 11) before passing through a 40 nm single
bandpass filter centered at 400 nm (Semrock FF01-400/40-25) or a 24 nm single bandpass
filter centered at 500 nm (Semrock FF01-500/24-25). LED output was then diverted 90° into a
50:50 beam splitter via a standard mirror (505 nm LED) or a 505 nm long pass dichroic mirror
(ThorLabs DMLP505R) (402 nm LED). Resulting LED outputs were split again via two 50:50
beam splitters resulting in four equal dual-wavelength light sources. Each resulting output was
focused onto one end of a bifurcated fiber bundle (Oriel 77565), only one of which is depicted in
Fig. 3. Fiber bundles consisted of a randomly-mixed, close-packed array of source and detection
fibers (individual fiber diameter: 55 µm, 0.56 NA, common bundle diameter: 4.5 mm, total
bundle length: 2 m). Light level was controlled by adjusting the amplitude of a 1.2 kHz (402
nm LED) or 1.6 kHz (505 nm LED) square-wave modulated LED driver signal from a Stanford
Research SR-830DSP lock in amplifier. Irradiance at the sample was set at 6 (402 nm) or 50
(505 nm) µW/cm2 .
After sample illumination, MB-301 and MB-404 fluorescence emission was collected by
the other fiber bundle bifurcation and collimated (Newport Corp., Model 77645). For the
sake of simplicity, only one of the four detection channels is depicted in Fig. 3. MB-301
fluorescence was diverted 90° via a 567 nm long-pass dichroic mirror (ThorLabs DMLP567),
passed through a 488 nm long-pass filter (Semrock LP02-488RE-25), a 15 nm bandpass filter
centered at 540 nm (Semrock FF01-540/15-25), and detected by a Hamamatsu H7827-011
photomultiplier tube (PMT) with built-in amplifier. MB-404 fluorescence passed through the
567 nm long-pass dichroic mirror, a 532nm long-pass filter (Semrock LP03-532RE-25), a 40
nm bandpass filter centered at 593 nm (Semrock FF01-593/40), and detected by a Hamamatsu
H7827-001 photomultiplier tube (PMT) with built-in amplifier. PMTs were powered by an
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Aligent E3630A power supply, and gains were adjusted via an inline potentiostat. Each amplified
PMT output was synchronously detected by a lock-in amplifier (Stanford Research, SR830DSP),
referenced to its respective source LED modulation frequency. Each lock-in amplifier output was
read, displayed, and saved at a rate of 1 Hz using LabView software.
2.6.

Transdermal fluorescence data analysis and calibration

Endogenous skin autofluorescence (baseline) contributed to the measured transdermal fluorescence signals for both the short and long wavelength measurements (MB-301 and MB-404
compounds respectively) and needed to be accounted for in relating the transdermal signals to
agent concentrations. The process of gavaging the animals with these agents disturbed the optical
measurements, resulting in a significant baseline shift on some of the animals. Therefore, rather
than relying on the pre-gavage baseline measurements, the initial baselines were determined
by back-extrapolating to the time zero gavage time, using a linear fit to the first five minutes
of data collected after the animals had been returned to the anesthesia manifold. This initial
(scalar) baseline was subtracted from the MB-404 fluorescence collected over the remainder of
the experiment. The baseline-corrected MB-404 fluorescence remained well above zero at the
end of the experiment (∼8 hours after gavage).
However, in the case of MB-301, scalar subtraction of the initial baseline resulted in the
corrected fluorescence signal dropping below zero, starting at about 4 hours after gavage. This
behavior is likely attributable to photobleaching of skin auto-fluorescence at the 400 nm excitation
wavelength. Previous experiments have shown that skin photo-bleaching is highly wavelength
dependent, with photo-bleaching increasing markedly with decreasing wavelength [28,29]. The
final MB-301 baseline was estimated by fitting an exponential with a variable offset to the final
5.5 hours of the experiment, and using the fitted offset term as the final baseline value. A linearly
varying baseline between the time of gavage and the end of the experiment was then used to
correct the full MB-301 fluorescence time course.
After baseline correction, the data were smoothed and decimated by applying a 60-second wide
trimmed mean filter, with exclusion of the lowest and highest quartiles of the sorted fluorescence
values. The time scale of each channel (animal) was shifted so that time zero corresponded to the
time of gavage.
To correct for the differing optical properties of the two molecules and the variation in instrument
sensitivity across the different instrument channels, a calibration procedure was developed. A
series of solutions was prepared containing MB-301 and MB-404 at equal concentrations (0, 31.3,
125, 500, 2000 ng/mL), and 1% Intralipid to mimic skin light scattering properties. Standards
were measured in each detection channel, using a 1 mm flow cell cuvette. Fluorescence signals
for each standard were plotted against agent concentration to obtain calibration responses for
each agent in each detection channel (Fig. 4). The non-zero fitted intercept on each channel is
indicative of a contribution to the signal due to leak-through of scattered excitation light. For
the animal measurements, the signal contribution due to excitation leak-through was corrected
along with skin auto-fluorescence by the baseline subtraction procedure described above, so only
the fitted in vitro calibration slopes were used to estimate the in vivo agent concentrations. The
substantial variation in slopes across the detection channels is due to variation in both optical
alignment and in differences in amplifier gain settings.
Additional solutions containing only one or the other or both of the molecules were then used
to assess the ability of the instrument to discriminate between the two molecules across the two
excitation and emission arms of the instrument. The discrimination errors for the low (MB-301)
and high (MB-404) molecular weight species, EL and EH , were defined as:
EL = 100 ∗

CL (H + L) − CL (L only)
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Fig. 4. Calibration of MB-404 and MB-301 in 1% Intralipid across the 4 detection channels.
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of interest is present (L only or H only). Concentrations of 500 and 5000 ng/mL were employed
respectively for the low (MB-301) and high (MB-404) molecular weight species. The results,
summarized in Table 1, show that the estimated discrimination errors were 10% or less, except
for one short wavelength channel, where the discrimination error for MB-301 was 26%. The high
variability in the discrimination errors across the instrument channels suggests that alignment
sensitivity is critical, but that under optimal alignment (e.g. Channel 1), discrimination errors of
less than 1% are achievable.
EH = 100 ∗

Table 1. Discrimination Error Estimates for Optically Determined Concentrations.
Discrimination Error by Detection Channel
Channel 1

Channel 2

EL

−0.6%

−7.2%

5.2%

26%

EH

0.8%

−0.2%

−8.6%

10%

3.
3.1.

Channel 3

Channel 4

Results
Fluorophore recovery in urine results

The data shown in Table 2 contain the animal status (injured or control), the total volume of urine
collected after eight hours, the concentration of MB-301 and MB-404 of dosing solution, the
weight of each animal used for determining the volume of dosing solution, the concentration

Research Article

Vol. 10, No. 10 / 1 October 2019 / Biomedical Optics Express

5110

(µg/mL) of MB-301 and MB-404 measured by the HPLC analysis, and the total mass amount
recovered in the urine.
Table 2. Parameters, analysis, and results of fluorophore recovery in urine samples. Blue indicates
injured rats, red indicates control rats.
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Fig. 5. MB-404 % recovery in Rat Urine. Blue bars are injured rats, red bars are control rats.

Fig. 5. MB-404% recovery in Rat Urine. Blue bars are injured rats, red bars are control rats.
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Figure 6 shows no definitive trend with respect to urine accumulation of MB-301 between the
injured vs control rats.
Table163 summarizes the average percent recovery in urine of MB-404 and MB-301 for the
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% Recovery MB-301

Figure 5 clearly shows that the injured rats have more MB-404 collected in the urine than
the control rats.
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Table 3 summarizes the average
urine of MB-404 and MB-301
for the
Compound
Injured percent recovery inControl
p-value (two-tail)
injured
and
control
animals.
The
MB-404
recovery
percentage
was
definitively
greater
for
the
MB-301
10.2 +/- 4.1
8.1 +/- 3.4
0.45
MB-404

9.2 +/- 3.4

1.2 +/- 0.5

0.02

For MB-301, the average percent recovery between the injured and control cohorts is not
as definitive. For this case, the two-sample t-test yields a two-tail p-value of 0.45, indicating
essentially no difference between these two cohorts.
3.2.

Transdermal fluorescence measurement analysis and results

The transdermal fluorescence measurements with baseline subtraction and conversion to concentration units from the calibration methodology are displayed in Fig. 7(a) and 7(b). The data are
from two independent experiments with two injured and two control rats in each experiment. In
Fig. 7(a), the MB-404 concentration time course for the injured animals clearly rises above the
level of the control animals within half an hour after gavage. The time to peak concentration is
highly variable among the treated animals, ranging from about one hour to greater than six hours.
At eight hours following gavage, the MB-404 concentration for three of the four animals remains
well above that of the controls.
In contrast, the MB-301 concentration time course plots, shown in Fig. 7(b), are highly
overlapping among the injured and control animals, with the data for only one of the injured
animals clearly distinct from the others. In all cases, for both injured and control animals, the
MB-301 concentration peaked in under two hours relative to the time of gavage. And by the end
of the eight-hour experiment, the MB-301 concentration has returned nearly to zero in all cases.
The common method of assessing gut permeability with sugar molecules is to plot the ratio of
the concentrations of high to low molecular weight agents over time. A ratio of the high to low
molecular weight fluorescent agents is shown in Fig. 8. Here again, a clear separation between
the injured and control rats is seen within a short (< 0.5 hour) time period. However, due to
the rapid clearance of the MB-301 compound, the ratio becomes increasingly noisy with time,
with large oscillations in some cases, as the concentration of the lower molecular weight species
approaches zero.
An analysis method to address the aforementioned issue is to compile the longitudinal area
under the curve (AUC) for each compound. The AUC ratio of high to low molecular weight

Research Article

Vol. 10, No. 10 / 1 October 2019 / Biomedical Optics Express

5112

Rat ID

6

1

Concentraon (μg/mL)

2
5
6

3

3
4
7
8

0
0

2

4

Time (Hrs.)

6

8

Fig. 7. (a). Concentration time-course of MB-404 derived from transdermal fluorophore
intensity measurements at 593 nm (with 505 nm excitation). Solid lines represent injured
rats, dashed lines represent control rats. Time zero represents the time of gavage. (b).
Concentration time-course of MB-301 derived from transdermal fluorophore intensity
measurements at 540 nm (with 402 nm excitation). Solid lines represent injured rats, dashed
lines represent control rats. Time zero represents the time of gavage.

compounds is shown in Fig. 9. This ratio remains stable and readily distinguishable between the
injured and control rats throughout the course of the experiment. Similar to Fig. 7(a), the time
course of the AUC ratio curves among the injured animals are highly variable, with the curve for
one animal asymptotically approaching a ratio of about two, and the curves for the remaining
three treated animals reaching between 7 and 10 by the end of the experiment, with little sign
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4. Discussion
The average percent recovery of fluorophore in urine summarized in Table 2 strongly
indicates that with indomethacin treatment, the larger molecule MB-404 permeates the gut
membrane and enters the blood stream to a much greater extent than in rats challenged with
vehicle alone, by nearly an order of magnitude. MB-301 permeates the gut membrane of
injured and control rats to an equivalent extent. Thus the fluorophore ratio methodology
essentially mimics the results of the dual sugar absorption test (DSAT) as initially
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Discussion

The average percent recovery of fluorophore in urine summarized in Table 2 strongly indicates
that with indomethacin treatment, the larger molecule MB-404 permeates the gut membrane and
enters the blood stream to a much greater extent than in rats challenged with vehicle alone, by
nearly an order of magnitude. MB-301 permeates the gut membrane of injured and control rats
to an equivalent extent. Thus the fluorophore ratio methodology essentially mimics the results of
the dual sugar absorption test (DSAT) as initially hypothesized.
In a similar manner, the concentration estimates based on transdermal measurements of agent
fluorescence clearly differentiated between the injured and control animals in the case of the high
molecular weight species MB-404, but were less differentiated for the low molecular weight
species MB-301. The added benefit of the transdermal measurements is that no sample collection
was required and the differentiation could be observed within less than 30 minutes after the time
of gavage.
These results naturally lead to the question of whether use of the low molecular weight agent
is necessary in order to assess gut permeability. This topic will be explored in future studies.
However, it should be pointed out that for humans in the general population the variability in gut
transit times and the agent elimination rates from the blood stream by the kidney is likely to be
much higher than the variability encountered between the laboratory-raised animals employed
in these experiments. Assuming that a ratio of high to low molecular weight compounds is
necessary to compensate for this variation, the AUC method offers the benefit of showing clear
differentiation between injured and control animals within half an hour after gavage and extending
over the entire duration of the experiment (approximately eight hours).
Another advantage of the ratiometric fluorescence technique employed here is that it can
compensate for wavelength-independent variations in optical collection efficiency occurring over
the course of the measurement, such as due to changes in probe angular positioning relative to
the skin. However, wavelength-dependent variations in the local skin properties, such as those
due to changes in local blood content, will not be corrected by measurement of fluorescence
alone. The addition of diffuse reflectance measurements to assess tissue property variations in
real time, therefore has the potential to improve the accuracy of the agent concentration estimates
[30]. Whether such accuracy improvements would translate to meaningful differences in clinical
assessment in GI permeability will be the subject of future experiments.
The variability in response across the four injured animals observed in this experiment may
simply be an indication of the varying efficacy of indomethacin to induce gut injury due to
biological variability of this animal model. The wide variation in time to peak concentration for
the higher molecular weight compound may also be an indication of variation in the location of
injury within the gut.
5.

Conclusion

In our previous publication, the fluorophore technology was shown to be more sensitive than
the DSAT method in the animal model for recovery of compounds in the urine (see Fig. 2 in
Reference 18). In this paper, we extend that work to completely biocompatible fluorophores.
Transdermal fluorescent detection of our dual fluorophore system mimics the DSAT results
without requiring specimen collection or sophisticated chemical analysis. This technology for
point-of-care determination of gut permeability should be easily adaptable to human use. A
clinical study is expected to commence shortly.
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